Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Change in Accured Expenses data on record, last reported at $43372.0 in Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 94.79% to $43372.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $611405.0, a 39.2% decrease, with the full-year FY2025 number at $1.4 million, up 233.57% from a year prior.
  • Change in Accured Expenses reached $43372.0 in Q1 2026 per IKT's latest filing, down from $424899.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for IKT hit a ceiling of $858240.0 in Q1 2022 and a floor of -$1.3 million in Q3 2022.
  • A 5-year average of $82876.1 and a median of $132394.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 15605.69% in 2022, then tumbled 273.47% in 2024.
  • Tracing IKT's Change in Accured Expenses over 5 years: stood at $132394.0 in 2022, then surged by 203.44% to $401740.0 in 2023, then rose by 29.1% to $518656.0 in 2024, then decreased by 18.08% to $424899.0 in 2025, then tumbled by 89.79% to $43372.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for IKT at $43372.0 in Q1 2026, $424899.0 in Q4 2025, and $718197.0 in Q3 2025.